Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Dako CDx for Merck's NSCLC Test

NEW YORK (GenomeWeb) – Agilent Technologies' Dako today said that the US Food and Drug Administration has approved the firm's companion diagnostic assay in connection with a simultaneous approval for Merck's non-small lung cancer drug. 

The companion diagnostic called PD-L1 IHC 22C3 pharmDx is used to determine whether a patient with advanced NSCLC is likely to respond to Merck's anti-PD-1 therapy Keytruda (pembrolizumab), which was approved by the FDA for treating patients with metastatic NSCLC whose tumors expressed PD-L1 and whose disease has progressed on or after platinum-containing chemotherapy. 

Dako's test, developed in partnership with Merck, will be used to determine whether the patient's tumor expresses the PD-L1 protein. Dako said that it hopes to gain regulatory clearance for the assay in Canada, Europe, and other jurisdictions next year. 

"The approval of the first PD-L1 diagnostic has the potential to provide information that will help guide treatment decisions for many patients," Roger Dansey, senior vice president at Merck Research Laboratories, said in a statement. 

Dako and Merck announced a deal to develop a CDx for Keytruda in May 2014.

Separately, Labortory Corporation and Quest Diagnostics each said that they will provide clinical laboratory testing using PD-L1 IHC 22C3 pharmDx. Physicians are able to order the test from either firms starting today. Also, GE Healthcare's Clarient is offering the test. 

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.